The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Seminars in Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 3120317
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dose intensity analysis of chemotherapy regimens in ovarian carcinoma.

  1987cited by this paper
• Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?

  1986cited by this paper
• Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: effects on both untreated and previously treated patients.

  1985cited by this paper
• Cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced endometrial carcinoma.

  1985cited by this paper
• Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin.

  1984cited by this paper
• High-dose cisplatin in hypertonic saline.

  1984cited by this paper
• Ovarian cancer treatment: progress or paralysis?

  1984cited by this paper
• Hexamethylmelamine and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapy.

  1982cited by this paper
• Single-agent adriamycin followed by combination hexamethylmelamine-cyclophosphamide for advanced ovarian carcinoma.

  1982cited by this paper
• cis-Dichlorodiammineplatinum (II) and hexamethylmelamine in advanced ovarian carcinoma: a phase II study.

  1982cited by this paper
• Cisplatin Chemotherapy for Disseminated Endometrial Cancer

  1982cited by this paper
• Treatment of chemotherapy-resistant advanced ovarian cancer with a combination of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-diamminedichloroplatinum (CHAP).

  1981cited by this paper
• Hexamethylmelamine in mustard-resistant ovarian adenocarcinoma.

  1981cited by this paper
• Cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin (CHAD) as second-line chemotherapy for ovarian adenocarcinoma.

  1981cited by this paper
• Doxorubicin and Cyclophosphamide Chemotherapy for Disseminated Endometrial Cancer

  1981cited by this paper
• USE OF HIGH DOSE CIS‐DICHLORODIAMMINE PLATINUM (II) (NSC—119875) † FOLLOWING FAILURE ON PREVIOUS CHEMOTHERAPY FOR ADVANCED CARCINOMA OF THE OVARY

  1981cited by this paper
• cis-Diamminedichloroplatinum(II) therapy for advanced ovarian cancer.

  1980cited by this paper
• A phase II study of Cis-platinum for recurrent corpus cancer.

  1980cited by this paper
• Cancer of the ovary: a summary of experience with cis-dichlorodiammineplatinum(II) at the Royal Marsden Hospital.

  1979cited by this paper
• cis-Dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group.

  1979cited by this paper
• Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma.

  1979cited by this paper
• Hexamethylmelamine in ovarian cancer resistant to cyclophosphamide and adriamycin.

  1979cited by this paper
• Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.

  1979cited by this paper
• The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II).

  1979cited by this paper
• cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer.

  1979cited by this paper
• Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer.

  1978cited by this paper
• Hexamethylmelamine in alkylating agent‐resistant ovarian carcinoma

  1978cited by this paper
• The efficacy of chemotherapeutic agents in the management of disseminated gynecologic cancer.

  1965cited by this paper
• Clinical appraisal of cyclophosphamide in malignant neoplasms

  1962cited by this paper

• Principles of Dose, Schedule, and Combination Therapy

  2019cites this paper
• Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

  2012cites this paper
• Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.

  2012cites this paper
• Maximal cytoreductive surgery and high dose cisplatin chemotherapy for advanced ovarian cancer.

  2010cites this paper
• Ginekologia 4.2009 srodek.indd

  2010cites this paper
• Age does not influence taxol dose intensity in recurrent carcinoma of the ovary

  2010cites this paper
• Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.

  2006cites this paper
• Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas.

  2005cites this paper
• An experimental study on the therapeutic effect of consecutive low-dose cisplatin with caffeine in sarcoma-bearing mice.

  2005cites this paper
• 300 mg/m2 carboplatin (Cb), adriamycin (A) cyclophosphamide (C) (CACb-300) combination in advanced ovarian carcinoma: a feasibility study

  2004cites this paper
• Calculation of received dose intensity for combinations of drugs using small-cell lung carcinoma treatment regimens as examples

  2004cites this paper
• Gemcitabine in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma.

  2004cites this paper
• Topotecan in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma

  2004cites this paper
• Inhibitory effects on pulmonary metastases of low-dose consecutive administration of cisplatin on sarcoma-bearing mice.

  2003cites this paper
• Biodegradable polymer–mediated intratumoral delivery of cisplatin for treatment of human head and neck squamous cell carcinoma in a chimeric mouse model

  2003cites this paper
• Is there any place for cytotoxic chemotherapy in endometrial cancer?

  2001cites this paper
• High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).

  2000cites this paper
• Radical cytoreductive surgery combined with platinums-carboplatin and cisplatin chemotherapy for advanced ovarian cancer.

  1999cites this paper
• Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group.

  1999cites this paper
• Future directions with taxane therapy.

  1999cites this paper
• Combination of cisplatin, epirubicin, and cyclophosphamide (PEC regimen) in advanced or recurrent endometrial cancer: a retrospective clinical study.

  1999cites this paper
• Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. GOCS (Gynecological Oncology Cooperative Study).

  1998cites this paper
• Pharmacokinetics and safety profile of oxaliplatin.

  1998cites this paper
• A phase I-II trial of fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer.

  1997cites this paper
• On the relationship between response to treatment and survival time.

  1996cites this paper
• [Dose optimization in clinical oncology: pharmacokinetic-pharmacodynamic relationship].

  1996cites this paper
• A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer.

  1996cites this paper
• Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma: Analysis of the literature

  1996cites this paper
• Irinotecan (CPT-11): pharmacology and clinical applications.

  1996cites this paper
• Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.

  1995cites this paper
• Clinical evaluation of human granulocyte colony-stimulating factor in chemotherapy for ovarian cancer.

  1995cites this paper
• [Chemotherapy of metastatic endometrial carcinoma. Review of the literature].

  1995cites this paper
• Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities.

  1995cites this paper
• Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity

  1994cites this paper
• Ondansetron and Metoclopramide Fail to Prevent Vomiting Secondary to Ultra‐High‐Dose Cisplatin‐Carboplatin Chemotherapy

  1994cites this paper
• Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines

  1994cites this paper
• Chemotherapy of metastatic endometrial cancer.

  1994cites this paper
• Phase I trial of cisplatin in combination with glutathione.

  1994cites this paper
• A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer

  1994cites this paper
• Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation study.

  1994cites this paper
• Dose-intensive chemotherapy in extensive-stage small cell lung cancer.

  1994cites this paper
• Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.

  1993cites this paper
• Dose intensification of cisplatin chemotherapy through biweekly administration.

  1993cites this paper
• The impact of received dose intensity on the outcome of advanced ovarian cancer.

  1993cites this paper
• Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.

  1993cites this paper
• High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.

  1993cites this paper
• Tamoxifen modulation of cisplatin cytotoxicity in human malignancies

  1993cites this paper
• High-dose biweekly intraperitoneal cisplatin: an effective way to increase cisplatin dose intensity.

  1993cites this paper
• Dose intensity analysis in advanced ovarian cancer patients.

  1993cites this paper
• Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC.

  1993cites this paper
• The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose‐intense taxol and granulocyte colony stimulating factor

  1993cites this paper
• Short‐duration (three cycles) cisplatin combination chemotherapy with alkylating agent consolidation in advanced epithelial ovarian cancer

  1992cites this paper
• Advances in the chemotherapy of gynecologic malignancies

  1992cites this paper
• Chemotherapy for urothelial tract malignancies: breaking the deadlock.

  1992cites this paper
• Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the Grupo Ginecologico Español para el Tratamiento Oncologico (GGETO).

  1991cites this paper
• The Integration of Whole Abdominal Radiotherapy and Intraperitoneal Cisplatin into the Primary Management of Advanced Ovarian Carcinoma

  1991cites this paper
• Measures of renal function in patients with cisplatin-related chronic renal disease.

  1991cites this paper
• Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions.

  1991cites this paper
• 5-Fluorouracil (FU) with folinic acid (FA) and mitomycin c (MMC) in the adjuvant treatment of colorectal carcinoma. part i. evaluation of toxicity

  1991cites this paper
• Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma.

  1991cites this paper
• Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma.

  1991cites this paper
• Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia.

  1991cites this paper
• Combined modality therapy of Hodgkin's disease: 10-year results of National Cancer Institute of Canada Clinical Trials Group multicenter clinical trial.

  1991cites this paper
• Altretamine

  1991cites this paper
• A five-drug alternating chemotherapy regimen for patients with advanced epithelial ovarian cancer.

  1990cites this paper
• Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate.

  1990cites this paper
• Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study.

  1990cites this paper
• Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.

  1990cites this paper
• Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease: a Gynecologic Oncology Group study.

  1990cites this paper
• Evaluation of cisplatin dose intensity: current status and future prospects.

  1989cites this paper
• Multiagent chemotherapy of endometrial carcinoma.

  1989cites this paper
• Clinical Pharmacokinetics-Pharmacodynamics of Anticancer Drugs

  1989cites this paper
• Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma.

  1988cites this paper